Next Article in Journal
Timing and Duration of Drug Exposure Affects Outcomes of a Drug-Nutrient Interaction During Ontogeny
Previous Article in Journal
Expression of Drug-Resistant Factor Genes in Hepatocellular Carcinoma Patients Undergoing Chemotherapy with Platinum Complex by Arterial Infusion
Pharmaceutics 2010, 2(3), 313-320; doi:10.3390/pharmaceutics2030313

Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson’s Disease

, , , ,  and *
Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
* Author to whom correspondence should be addressed.
Received: 1 June 2010 / Revised: 26 August 2010 / Accepted: 14 September 2010 / Published: 20 September 2010
View Full-Text   |   Download PDF [232 KB, uploaded 20 September 2010]   |   Browse Figure


Application of oral fast release amantadine and levodopa may induce an improvement of motor symptoms in patients with Parkinson’s disease (PD). The objective of this trial was to investigate the clinical efficacy of a fast release amantadine sulfate formulation on simple and complex movement performance and putative relations to the pharmacokinetic behavior in PD patients. We challenged two cohorts of 12 PD patients, who were taken off their regular antiparkinsonian treatment for at least 12 hours, with oral 300 mg amantadine sulfate. We scored motor symptoms and performed instrumental tasks, which ask for performance of simple or complex motion series under cued conditions. Motor symptoms and performance of complex movements significantly improved in contrast to the carrying-out of simple motions. N-methyl-D-aspartic acid antagonistic and dopaminomimetic amantadine also influences altered higher predominant prefrontal cognitive functions. Therefore, performance of complex motion series improved, whereas carrying-out of simple repetitive movements is more associated to the striatal dopamine dependent basal ganglia function.
Keywords: Parkinson’s disease; amantadine; motion; cognition Parkinson’s disease; amantadine; motion; cognition
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Muhlack, S.; Müsch, P.; Konietzka, S.; Woitalla, D.; Przuntek, H.; Müller, T. Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson’s Disease. Pharmaceutics 2010, 2, 313-320.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert